Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS005 in Active Ankylosing Spondylitis
NCT05212051Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roconkibart in ankylosing spondylitis (AS) (6 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Assessment of SpondyloArthritis international Society 20 response at 16 weeks. Started Apr 2021; status: completed.
02
Drugs
roconkibart
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT05212051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05212051.